Correct Answer: C. Factor Xa inhibitor
Apixaban is a selective, reversible Factor Xa inhibitor belonging to the newer class of direct oral anticoagulants (DOACs). It directly inhibits activated Factor X (Factor Xa) in the intrinsic and common coagulation pathways, preventing the conversion of prothrombin to thrombin and thus blocking thrombin generation. Unlike parenteral anticoagulants (heparin, fondaparinux), apixaban is orally bioavailable and does not require monitoring of INR or aPTT. In Indian clinical practice, apixaban is increasingly used for stroke prevention in non-valvular atrial fibrillation (per NHIS guidelines), venous thromboembolism prophylaxis post-orthopedic surgery, and treatment of DVT/PE. The drug has a predictable pharmacokinetic profile, rapid onset (peak levels in 3 hours), and is administered at fixed doses (5 mg or 2.5 mg twice daily depending on indication). Its mechanism—direct Factor Xa inhibition—distinguishes it from direct thrombin inhibitors (dabigatran, which inhibit Factor IIa) and from indirect anticoagulants like warfarin (which inhibit vitamin K-dependent factors) and heparin (which potentiates antithrombin III).
Why the other options are wrong
A. Parenteral direct thrombin inhibitor — This is wrong because apixaban is oral, not parenteral. Parenteral direct thrombin inhibitors include argatroban and bivalirudin (IV only). Apixaban's defining feature is oral bioavailability, making it a DOAC. The trap is confusing apixaban with parenteral anticoagulants or assuming all direct inhibitors are given parenterally. B. Antifibrinolytic — This is wrong because apixaban is an anticoagulant, not an antifibrinolytic. Antifibrinolytics (tranexamic acid, epsilon-aminocaproic acid) inhibit fibrinolysis and are used for bleeding control in surgery or hemophilia. Apixaban prevents clot formation upstream, not fibrin breakdown. This is a category confusion trap. D. Oral direct thrombin inhibitor — This is wrong because apixaban inhibits Factor Xa, not thrombin (Factor IIa). The only oral direct thrombin inhibitor is dabigatran (Pradaxa). Apixaban and rivaroxaban are Factor Xa inhibitors; edoxaban is also Factor Xa. The trap conflates 'oral DOAC' with 'direct thrombin inhibitor'—students may pick this if they remember apixaban is oral but forget its specific target.
High-Yield Facts
- Apixaban is a selective, reversible Factor Xa inhibitor (not Factor IIa/thrombin).
- DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) are oral anticoagulants with fixed dosing and no INR monitoring required.
- Dabigatran is the only oral direct thrombin inhibitor; all others (apixaban, rivaroxaban, edoxaban) are Factor Xa inhibitors.
- Apixaban dosing: 5 mg BD for AF/VTE treatment; 2.5 mg BD in elderly/low-weight patients or post-orthopedic surgery prophylaxis.
- Reversal agent for apixaban: apixaban-specific antidote (apixaban-binding aptamer) is not widely available in India; fresh frozen plasma or prothrombin complex concentrate used off-label.
Mnemonics
DOAC Factor Targets Dabigatran = IIa (Thrombin); Apixaban, Rivaroxaban, Edoxaban = Xa. Memory: 'D for Dabigatran = Direct thrombin (IIa)'; rest target Xa. Oral Anticoagulants in India WARE: Warfarin (vitamin K antagonist, needs INR); Apixaban, Rivaroxaban, Edoxaban (DOACs, fixed dose, no monitoring).
NBE Trap
NBE pairs 'oral' + 'direct inhibitor' to lure students into picking dabigatran (option D). The discriminator is the specific coagulation factor: apixaban targets Xa, dabigatran targets IIa (thrombin). Students who remember "apixaban is a DOAC" but forget the target enzyme fall into this trap.
Clinical Pearl
In Indian hospitals, apixaban is now preferred over warfarin for AF stroke prevention due to superior efficacy, no dietary interactions, and no INR monitoring—critical in resource-limited settings. However, cost and renal clearance (avoid if CrCl <15 mL/min) remain barriers in public health systems.
_Reference: KD Tripathi Pharmacology Ch. 48 (Anticoagulants & Antiplatelets); Harrison Ch. 139 (Antithrombotic Therapy)_